Table 2.
Comparison of pre- and post-chemoradiotherapy (CRT) and relative change in 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)-derived parameters in patients who never developed distant disease during follow-up (local disease only) and those did develop metastatic disease
| Parameter | Local disease only during follow-up Median (range) |
Developed distant disease during follow-up Median (range) |
Significance P value (Mann-Whitney U test) |
|---|---|---|---|
| Baseline tumour volume (cm3) | 21.6 (1.6 to 38.0) | 32.9 (11.3 to 80.2) | 0.202 |
| Pre-SUVmax | 3.8 (2.6 to 6.2) | 8.6 (4.0 to 15.6) | 0.002 |
| Pre-SUVpeak | 2.5 (2.0 to 4.5) | 7.5 (4.5 to 13.5) | 0.002 |
| Pre-SUVmean | 1.8 (1.6 to 1.9) | 3.3 (2.2 to 5.6) | 0.001 |
| Pre-SUVmedian | 1.7 (1.4 to 1.9) | 3.0 (2.5 to 5.2) | 0.002 |
| Pre-TLG | 26.9 (16.8 to 53.3) | 115.9 (35.2 to 208.8) | 0.006 |
| Post-SUVmax | 2.0 (1.6 to 3.5) | 4.9 (1.7 to 7.9) | 0.045 |
| Post-SUVpeak | 1.7 (1.6 to 2.3) | 4.3 (1.3 to 6.2) | 0.102 |
| Post-SUVmean | 1.4 (1.1 to 1.4) | 2.2 (1.1 to 3.3) | 0.060 |
| Post-SUVmedian | 1.3 (1.1 to 1.3) | 1.9 (1.1 to 2.8) | 0.130 |
| Post-TLG | 17.2 (8.8 to 36.7) | 36.6 (15.1 to 167.5) | 0.102 |
| %ΔSUVmax | −43.6 (−24.5 to −59.8) | −45.7 (97.5 to −80.9) | 0.785 |
| %ΔSUVpeak | −31.7 (−17.8 to −48.1) | −45.2 (51.2 to −83.3) | 0.384 |
| %ΔSUVmean | −27.0 (−19.8 to −35.1) | −42.2 (8.6 to −67.0) | 0.130 |
| %ΔSUVmedian | −25.4 (−13.6 to −30.0) | −45.2 (51.3 to −83.3) | 0.202 |
| %ΔTLG (%) | −35.2 (−30.0 to −47.7) | −56.5 (4.0 to −93.0) | 0.296 |
SUV, standardised uptake value; TLG, total lesion glycolysis.